Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial

Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes. The randomised placebo-controlled Diabetes...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2011-03, Vol.6 (3), p.e17554
Main Authors: Martin, Stephan, Herder, Christian, Schloot, Nanette C, Koenig, Wolfgang, Heise, Tim, Heinemann, Lutz, Kolb, Hubert
Format: Article
Language:English
Subjects:
Adult
Analysis
Atorvastatin
Atorvastatin Calcium
Autoantibodies
Autoimmune diseases
Autoimmunity
Beta cells
C-Peptide - secretion
C-reactive protein
Cholesterol
Clinical trials
Cytokines
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 1 - diagnosis
Diabetes Mellitus, Type 1 - drug therapy
Diabetes Mellitus, Type 1 - physiopathology
Diabetes therapy
Drug dosages
Fasting
Female
Females
Glycated Hemoglobin A - metabolism
Heptanoic Acids - adverse effects
Heptanoic Acids - pharmacology
Heptanoic Acids - therapeutic use
Humans
Insulin-Secreting Cells - drug effects
Insulin-Secreting Cells - pathology
Lipids - blood
Lymphocytes
Male
Medicine
Metabolism
Nervous system
Patients
Peptides
Pyrroles - adverse effects
Pyrroles - pharmacology
Pyrroles - therapeutic use
Randomization
Rodents
Signal transduction
Statins
Treatment Outcome
Type 1 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes. The randomised placebo-controlled Diabetes and Atorvastatin (DIATOR) Trial included 89 patients with newly diagnosed type 1 diabetes and islet autoantibodies (mean age 30 years, 40% females), in 12 centres in Germany. Patients received placebo or 80 mg/d atorvastatin for 18 months. As primary outcome stimulated serum C-peptide levels were determined 90 min after a standardized liquid mixed meal. An intent-to-treat analysis was performed. Fasting and stimulated C-peptide levels were not significantly different between groups at 18 months. However, median fasting serum C-peptide levels dropped from baseline to 12 and 18 months in the placebo group (from 0. 34 to 0.23 and 0.20 nmol/l, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0017554